NovaBay Pharmaceuticals, Inc.
NBY
$1.02
$0.088.50%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -70.38% | -50.72% | -33.72% | -6.77% | -20.01% |
| Total Other Revenue | -133.33% | 600.00% | -- | -- | -77.50% |
| Total Revenue | -70.44% | -50.59% | -33.47% | -6.45% | -20.21% |
| Cost of Revenue | 26.33% | -56.07% | -77.78% | -81.54% | -80.58% |
| Gross Profit | 42.57% | -45.28% | -66.50% | -75.31% | -83.97% |
| SG&A Expenses | 11.42% | 8.60% | -7.43% | -17.34% | -38.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 13.30% | -2.97% | -26.93% | -36.74% | -50.96% |
| Operating Income | -6.51% | -35.09% | -44.81% | -68.21% | -14.46% |
| Income Before Tax | 8.06% | -3.99% | -12.05% | -34.27% | 31.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.06% | -3.99% | -12.05% | -34.27% | 31.55% |
| Earnings from Discontinued Operations | 860.39% | 568.43% | 463.33% | 129.41% | -33.09% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 132.05% | 131.17% | 132.94% | 25.07% | 26.34% |
| EBIT | -6.51% | -35.09% | -44.81% | -68.21% | -14.46% |
| EBITDA | -6.90% | -35.83% | -45.82% | -69.54% | -17.11% |
| EPS Basic | 100.93% | 98.95% | 98.51% | 75.05% | 66.63% |
| Normalized Basic EPS | 96.67% | 94.26% | 93.57% | 53.63% | 57.02% |
| EPS Diluted | 100.92% | 98.94% | 98.50% | 75.05% | 66.63% |
| Normalized Diluted EPS | 96.70% | 94.28% | 93.58% | 53.63% | 57.02% |
| Average Basic Shares Outstanding | 851.51% | 1,162.44% | 2,780.10% | 2,070.97% | 679.09% |
| Average Diluted Shares Outstanding | 855.58% | 1,169.10% | 2,799.83% | 2,070.97% | 679.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |